BACKGROUND: The value of adjuvant chemotherapy for patients with positive lymph nodes (+LNs) after induction therapy and resection of esophageal cancer is controversial. This study assesses survival benefit of adjuvant chemotherapy in this cohort. METHODS: We analyzed our single-institution database for patients with +LNs after induction therapy and resection of primary esophageal cancer between 2000 and 2013. Factors associated with survival were analyzed using a Cox proportional hazards model. RESULTS: A total of 101 of 764 esophagectomy patients received induction and had +LNs on final pathologic examination. Forty-five also received adjuvant therapy: 37 of 45 (82%) received chemotherapy alone, 1 of 45 (2%) received radiation alone, and 7 of 45 (16%) received both. Pathologic stage was IIB in 21 (47%), IIIA in 19 (42%), and IIIB in 5 (11%). In 56 node-positive patients with induction but not adjuvant therapy, pathologic stage was IIB in 28 (50%), IIIA in 18 (32%), IIIB in 7 (13%), and IIIC in 3 (5%). Neither age nor comorbidity score differed between cohorts. Adjuvant patients experienced a shorter hospital length of stay (mean, 10 days [range, 6 to 33 days] versus 11 days [range, 7 to 67 days]; p = 0.03]. Median survival favored the adjuvant group: 24.0 months (95% confidence interval, 16.6 to 32.2 months) versus 18.0 months (95% confidence interval, 11.1 to 25.0 months); p = 0.033). Multivariate Cox regression identified adjuvant therapy, length of stay, and number of +LNs as influential for survival. CONCLUSIONS: Optimal management of node-positive patients after induction therapy and esophagectomy remains unclear, but in this series, adjuvant therapy, length of stay, and number of +LNs impacted survival. A prospective trial may reduce potential bias and guide the evaluation of adjuvant therapy in this patient population.
BACKGROUND: The value of adjuvant chemotherapy for patients with positive lymph nodes (+LNs) after induction therapy and resection of esophageal cancer is controversial. This study assesses survival benefit of adjuvant chemotherapy in this cohort. METHODS: We analyzed our single-institution database for patients with +LNs after induction therapy and resection of primary esophageal cancer between 2000 and 2013. Factors associated with survival were analyzed using a Cox proportional hazards model. RESULTS: A total of 101 of 764 esophagectomy patients received induction and had +LNs on final pathologic examination. Forty-five also received adjuvant therapy: 37 of 45 (82%) received chemotherapy alone, 1 of 45 (2%) received radiation alone, and 7 of 45 (16%) received both. Pathologic stage was IIB in 21 (47%), IIIA in 19 (42%), and IIIB in 5 (11%). In 56 node-positive patients with induction but not adjuvant therapy, pathologic stage was IIB in 28 (50%), IIIA in 18 (32%), IIIB in 7 (13%), and IIIC in 3 (5%). Neither age nor comorbidity score differed between cohorts. Adjuvant patients experienced a shorter hospital length of stay (mean, 10 days [range, 6 to 33 days] versus 11 days [range, 7 to 67 days]; p = 0.03]. Median survival favored the adjuvant group: 24.0 months (95% confidence interval, 16.6 to 32.2 months) versus 18.0 months (95% confidence interval, 11.1 to 25.0 months); p = 0.033). Multivariate Cox regression identified adjuvant therapy, length of stay, and number of +LNs as influential for survival. CONCLUSIONS: Optimal management of node-positive patients after induction therapy and esophagectomy remains unclear, but in this series, adjuvant therapy, length of stay, and number of +LNs impacted survival. A prospective trial may reduce potential bias and guide the evaluation of adjuvant therapy in this patient population.
Authors: Lucian R Chirieac; Stephen G Swisher; Jaffer A Ajani; Ritsuko R Komaki; Arlene M Correa; Jeffrey S Morris; Jack A Roth; Asif Rashid; Stanley R Hamilton; Tsung-Teh Wu Journal: Cancer Date: 2005-04-01 Impact factor: 6.860
Authors: A Herskovic; K Martz; M al-Sarraf; L Leichman; J Brindle; V Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami Journal: N Engl J Med Date: 1992-06-11 Impact factor: 91.245
Authors: Adam C Berger; Jeffrey Farma; Walter J Scott; Gary Freedman; Louis Weiner; Jonathan D Cheng; Hao Wang; Melvyn Goldberg Journal: J Clin Oncol Date: 2005-03-21 Impact factor: 44.544
Authors: Thomas W Rice; David J Adelstein; Mark A Chidel; Lisa A Rybicki; Malcolm M DeCamp; Sudish C Murthy; Eugene H Blackstone Journal: J Thorac Cardiovasc Surg Date: 2003-11 Impact factor: 5.209
Authors: Michael Stahl; Martin K Walz; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Jorge Riera-Knorrenschild; Peter Langer; Rita Engenhart-Cabillic; Michael Bitzer; Alfred Königsrainer; Wilfried Budach; Hansjochen Wilke Journal: J Clin Oncol Date: 2009-01-12 Impact factor: 44.544
Authors: C Rizzetto; S R DeMeester; J A Hagen; C G Peyre; J C Lipham; T R DeMeester Journal: J Thorac Cardiovasc Surg Date: 2008-05-23 Impact factor: 5.209
Authors: Christian G Peyre; Jeffrey A Hagen; Steven R DeMeester; Nasser K Altorki; Ermanno Ancona; S Michael Griffin; Arnulf Hölscher; Toni Lerut; Simon Law; Thomas W Rice; Alberto Ruol; Jan J B van Lanschot; John Wong; Tom R DeMeester Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Nasser K Altorki; Xi Kathy Zhou; Brendon Stiles; Jeffrey L Port; Subroto Paul; Paul C Lee; Madhu Mazumdar Journal: Ann Surg Date: 2008-08 Impact factor: 12.969
Authors: Tara R Semenkovich; Melanie Subramanian; Yan Yan; Wayne L Hofstetter; Arlene M Correa; Stephen D Cassivi; Matthew L Inra; Brendon M Stiles; Nasser K Altorki; Andrew C Chang; Alexander A Brescia; Gail E Darling; Frances Allison; Stephen R Broderick; Eric W Etchill; Felix G Fernandez; Ray K Chihara; Virginia R Litle; Juan A Muñoz-Largacha; Benjamin D Kozower; Varun Puri; Bryan F Meyers Journal: Ann Thorac Surg Date: 2019-06-20 Impact factor: 4.330
Authors: Nasser Davarzani; Gordon G A Hutchins; Nicholas P West; Lindsay C Hewitt; Matthew Nankivell; David Cunningham; William H Allum; Elizabeth Smyth; Nicola Valeri; Ruth E Langley; Heike I Grabsch Journal: Histopathology Date: 2018-03-25 Impact factor: 5.087